According to Crown, the fast-growing skin health company headquartered in Johnson City, TN, Xycrobe technology targets specific skin conditions and cosmetic treatments by using an isolated, live strain of skin-related bacteria.
Xycrobe technology harnesses the power of a specific strain of Cutibacterium acnes subsp. defensivees (C. acnes defensivees), a subspecies of the most prolific skin-specific bacterial species, accounting for an average of 89% of the bacteria in the sebum skin follicles to improve the health and appearance of the skin Skin by curating and supporting the right strain within the existing microbiome.
The results of the recently published study show that Crown’s Biojuve regimen, which contains both the Xycrobe strain and its ferment, supports a healthy skin environment, promotes increased skin hydration, reduces redness, regulates sebum production and reduces the appearance of signs of Reduces skin aging such as fine lines and photodamage.
Biojuve is a new dermatologist-derived product regimen currently in soft-launch. The range is expected to launch in 2023 and will be sold in the US by the Crown Aesthetics team, according to company officials.
“The research we present in this article debunks numerous myths that have perpetuated over the last half century or so about what constitutes a healthy skin microbiome, the role of C. acnes strains in skin health, and the ability to progressively treat topical Formulating products with live microbes could contribute to a healthier skin biome overall,” said Dr. Thomas M. Hitchcock, PhD, Chief Science Officer, Crown Laboratories Inc. We plan to continue investing in research into the relationship between the microbes that live on and in of the skin and how this new philosophy of formulating topical products to look at the skin biome holistically can transform the way we care for our skin.”
“Traditionally, the medical focus for topical skin care products has always been how a particular ingredient may affect the overall health of skin cells, with minimal consideration of how the ingredients affect the skin’s microflora or microbiome,” added Dr. Doris Day, Board Member, Board-Certified Dermatologist and Research Study Participant. “The proven effectiveness of this patented Xycrobe technology reinforces the notion that the human body depends on symbiosis. I expect this research will diversify the way physicians approach the health and treatment of skin diseases.”
Subjects in this eight-week study used a 5- or 7-point Likert scale (agree/disagree/disagree) over a two-month assessment period. Consistent responses at the 90th percentile or higher included (improved) skin texture, tone, healthy, natural appearance, felt conditioned, radiant, and alive (n=121*).
The full study of the effectiveness of Xycrobe, along with the results, has been made available to the public.